Nov 07, 2022 / 01:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Third Quarter 2020 Financial Results Conference Call and Webcast. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Executive Director of Investor Relations. You may begin.
Andrew Faughnan - Amicus Therapeutics, Inc. - Senior Director of IR
Thank you, Shannon. Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics' Third Quarter 2022 Financial Results and Corporate Highlights.
Leading today's call, we have Bradley Campbell, President and Chief Executive Officer; Daphne Quimi, Chief Financial Officer; and Sébastien Martel, Chief Business Officer; and Dr. Jeffrey Castelli, Chief Development Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer; and Ellen Rosenberg, Chief Legal Officer.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities
Q3 2022 Amicus Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot